产品名称
Anti-PDE9A Antibody, from rabbit
biological source
rabbit
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, rhesus macaque, mouse
species reactivity (predicted by homology)
chimpanzee (based on 100% sequence homology), rat (based on 100% sequence homology)
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... PDE9A(5152)
Analysis Note
Control
Human spleen tissue lysate
Human spleen tissue lysate
Evaluated by Western Blot in human spleen tissue lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected PDE9A in 10 µg of human spleen tissue lysate.
Western Blot Analysis: 0.5 µg/mL of this antibody detected PDE9A in 10 µg of human spleen tissue lysate.
Application
Detect PDE9A using this Anti-PDE9A Antibody validated for use in Western Blotting, IHC(P).
Research Category
Neuroscience
Neuroscience
Research Sub Category
Signaling Neuroscience
Signaling Neuroscience
Western Blot Analysis: A representative lot of this antibody detected PDE9A in human liver tissue lysate, and in mouse spleen and liver tissue lysates.
Immunohistochemistry Analysis: A 1:100 dilution of this antibody detected PDE9 in human prostate tissue, and in possible golgi type II and basket cells in the Purkinje and molecular layers of mouse cerebellum.
Immunohistochemistry Analysis: A 1:100 dilution of this antibody detected PDE9 in human prostate tissue, and in possible golgi type II and basket cells in the Purkinje and molecular layers of mouse cerebellum.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
PDE9A is a ubiquitous protein belonging to the cyclic nucleotide phosphodiesterase family which regulate the signaling of cyclic nucleotides such as cGMP and cAMP. PDE9A has a higher affinity for cGMP. It contains a catalytic site that associates with cofactors and hydrolyzes cGMP thereby terminating cGMP signaling for a number of cellular processes. PDE9A has been indirectly linked to signaling pathways involved in cognitive processes. Previous studies suggested that inhibition of PDE9A enhanced long-term potentiation (a widely studied mechanism of learning and memory); PDE9A may also effect changes in the plasticity of hippocampal neurons which are also important for certain types of cognitive processes. In addition to the brain, PDE9A is also highly expressed in the spleen, prostate, colon, kidney, and heart and may be involved in a range of physiological processes in these systems, via cGMP-amplified signaling.
~75 kDa observed. Uniprot describes 16 isoforms produced by alternative splicing, which have been observed at various molecular weights. (Kruse, L.S., et al. (2009). Brain Res. 1281: 25-34; Rentero, C., et al. (2003). Biochem Biophys Res Commun. 301(3):686-692.)
Immunogen
KLH-conjugated linear peptide corresponding to human PDE9A.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Protein A purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Dong I Lee et al.
Nature, 519(7544), 472-476 (2015-03-25)
Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease. However, cGMP
Elisa Landucci et al.
ACS chemical neuroscience, 14(20), 3826-3838 (2023-09-20)
In the central nervous system, some specific phosphodiesterase (PDE) isoforms modulate pathways involved in neuronal plasticity. Accumulating evidence suggests that PDE9 may be a promising therapeutic target for neurodegenerative diseases. In the current study, computational techniques were used to identify
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持